



## ABSTRACTS/PRESENTATIONS

*Last Updated: February 5, 2026*

### Submitted

1. Mandishora RSD, Pascoe M, Shamu T, Coghill AE, Wilkin T, Luethy R. Trends in Vulval Lesions Among Women Living with HIV at Newlands Clinic, Harare, Zimbabwe, 2012–2025. *AIDS 2026, the 26th International AIDS Conference*. Rio de Janeiro, Brazil. July 26-31, 2026.
2. Sandoval MM, La Rosa L, Svidler López L, Presencia G, Zalazar V, Arguello A, Ceschel M, Cardozo NF, Devisich G, Gun A, Grinpelc A, Tejo M, Figurelli S, Estefanía Rodríguez J, Pérez C, Figueroa MI, Arístegui I, Fink V. Expanding Anal Cancer Prevention: Pilot Study on Anal Cancer Screening according to International Guidelines Among People Living with HIV in Argentina. *AIDS 2026, the 26th International AIDS Conference*. Rio de Janeiro, Brazil. July 26-31, 2026.
3. Wong-Sefidan I, Kwon D, Ambinder R, Noy A, Henry D, Baiocchi R, Rubinstein P, Ramos JC, Dittus C, Ratner L, Cesarman E, Sparano J, Reid E, for the Consortium for Advancing Management and Prevention of Cancer in People with HIV (AMC). Integrating BTK Inhibition Into R-da-EPOCH for HIV-Related DLBCL. *ASCO Genitourinary Cancers Symposium (ASCO GU 2026)*. San Francisco, CA. February 26-28, 2026. **[AMC-101]**
4. Zalazar V, Serrao C, Aristegui I, Cardozo NF, Fabian S, Devisich G, Presencia G, Svidler López L, La Rosa L, Fink V, Sandoval M. When Shame Does Not Outweigh Care: Experiences, Perceptions, Emotional Attitudes and Acceptability of Anal Cancer Screening Among People Living with HIV in Argentina. *AIDS 2026, the 26th International AIDS Conference*. Rio de Janeiro, Brazil. July 26-31, 2026.
5. Zeltman A, Serrao C, Zalazar V, Cardozo NF, Fabian S, Devisich G, Aristegui I, Presencia G, Svidler López L, La Rosa L, Fink V, Sandoval M. Knowledge of Anal Cancer Risk Factors, Symptoms, and Screening Among People Living with HIV in Argentina. *AIDS 2026, the 26th International AIDS Conference*. Rio de Janeiro, Brazil. July 26-31, 2026.
6. Zou Y, Pluta L, Kang M, Ambinder RF, Krown SE, Campbell TB, Epeldegui M, Borok MZ, Hosseinipour MC, Dittmer DP, for the A5264/AMC067 Team. Kaposi Sarcoma Herpesvirus in Plasma: Association with Treatment Failure in Limited-stage, Treatment-naïve AIDS-KS. 2026 CROI (Conference on Retroviruses and Opportunistic Infections). February 22-25, 2026. Denver, CO. **[AMC-067]**

---

### 2025

1. Barta S, Noy A, Ahn KW, Patel J, Hunt T, Ibrahim U, Baiocchi R, Kwon D, Pasquini M, Ambinder R. CD19-directed CAR T-cell Therapy for B-cell Lymphoid Malignancies is Safe and Effective in People Living with HIV (PWH) – A Matched Cohort Analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR) and the AIDS Malignancy Consortium (AMC). Oral presentation. *67th American Society of Hematology (ASH) Annual Meeting*. Orlando, FL. December 6-9, 2025. **[AMC-113]**



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

2. Noy A, Barta SK, Van Hyfte G, Kwon D, Baiocchi R, Ramos JC, Rubinstein P, Chadburn A, and Ambinder R on behalf of the AIDS Malignancy Consortium. Daratumumab with Dose-Adjusted EPOCH Feasibility and Early Efficacy in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105. Poster presentation. *67th American Society of Hematology (ASH) Annual Meeting*. Orlando, FL. December 6-9, 2025. **[AMC-105]**
3. Vogt SL, Kwon D, Simwinga L, Busakhala N, Okuku F, Krown SE. Phase II Multicenter AIDS Malignancy Consortium Study of Pomalidomide in HIV-Associated Kaposi Sarcoma in Africa. *15th AORTIC (African Organisation for Research and Training in Cancer) International Conference on Cancer in Africa*. Hammamet, Tunisia. November 2-5, 2025. **[AMC-100]**
4. Maillie L, Sisk M, Coghill A, Van Bibber N, Guerra C, Aboulafia DM, Atkinson TM, Barta SK. Geospatial Access to CAR-T Clinical Trials for Non-Hodgkin Lymphoma in the United States: Are Persons with HIV Included? *AACR Conference on The Science of Cancer Health Disparities*. Baltimore, MD. September 20, 2025.
5. Maillie L, Sisk M, Coghill A, Guerra C, Aboulafia DM, Atkinson TM, Barta SK. Geospatial Disparities in Access to Clinical Trials for AIDS-defining Malignancies in the Continental United States. *Journal of Clinical Oncology*. June 2025; 43(16\_suppl):e13735-e13735. Published presentation. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. May 30-June 3, 2025. ([https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.16\\_suppl.e13735](https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.16_suppl.e13735))
6. Anderson JS, Beegle J, Stewart D, Dyer C, Buck A, Donatelli J, Shah G, Asmuth D, Pollard RB, Heinrich T, Noy A, Abedi M. Engraftment and HIV Resistance of Gene Modified Peripheral Blood Cells in a Phase I Trial of an HIV Stem Cell Gene Therapy: AIDS Malignancy Consortium 097. Published presentation. *American Society of Gene + Cell Therapy (ASGCT)*. New Orleans, LA. May 13-17, 2025. **[AMC-097]**
7. Maillie L, Sisk M, Coghill A, Guerra C, Aboulafia DM, Atkinson TM, Barta SK. State and Regional Disparities in Geospatial Access to Clinical Trials for AIDS-Defining Malignancies in the Continental United States. *Summit on Cancer Health Disparities (SCHD25)*. Seattle, WA. April 26, 2025. (<https://education.binaytara.org/content/seattle-summit-cancer-health-disparities-april-2025#group-tabs-node-course-default1>)
8. Anderson JS, Beegle J, Stewart D, Dyer C, Buck A, Donatelli J, Shah G, Asmuth D, Pollard RB, Heinrich T, Noy A, Abedi M. Phase I Clinical Trial AMC-097 Evaluating Engraftment and HIV Resistance of Gene Modified Blood Cells. *Conference on Retroviruses and Opportunistic Infections (CROI)*. San Francisco, CA. March 9-12, 2025. **[AMC-097]**

### 2024

9. Hamby M, Egleston B, Frosch Z, Steiner R, Noy A, Carvajal V, Tolu S, Jean-Louis G, Amengual J, Patel R, Ahmed S, Voorhees T, Baiocchi R, Meid K, Eurell A, Castillo J, Hamburger E, Dittus C, Nizamuddin I, Mehta-Shah N, Thaw dar N, Sandoval-sus J, Rojek A, Riedell P, Rubinstein P, Ariotti A, Suneja G, Vartanov A, Milrod C, Olszewski A, Smilnak G, Ayers E, Desai S, Rhodes J, Magarelli G, Feldman T, Najjar A, Pellon M, Aboulafia D, Galvez C, Bhatlapenumarthy V, Hamadani M, Barta SK. Improving Outcomes in Plasmablastic Lymphoma: A Multicenter



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

Experience from an American Cohort. Oral presentation. *66th American Society of Hematology (ASH) Annual Meeting*. San Diego, CA. December 7-10, 2024.

10. Noy A, Barta S, Kwan D, Baiocchi R, Ramos JC, Rubinstein P, Ambinder R, on behalf of the AIDS Malignancy Consortium. Feasibility Results of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105. Oral presentation. *66th American Society of Hematology (ASH) Annual Meeting*. San Diego, CA. December 7-10, 2024. **[AMC-105]**
8. Epeldegui M, Moser C, Choi Y, Borok M, Campbell T, MacPhail P, Martinez-Maza O, Krown SE for the AMC-066/A5263 Protocol Team. Association of Soluble Serum Biomarkers with Tumor Burden and Treatment Response in Advanced HIV-Related Kaposi Sarcoma in Resource-Limited Settings. Oral presentation. *19th International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 24-25, 2024. **[AMC-066]**
9. Gorejena-Chidawanyika P, Borok MZ, Robertson L, Chikwasha V, Ferrand R, Bohlius J, Muchengeti M, Ndlovu N. The Spectrum of Malignancies in Adolescents and Young Adults Living with HIV (AYALHIV) in Harare, Zimbabwe: A Retrospective Descriptive Review of the Cancer Registry Data. Poster presentation. *AIDS 2024, the 25th International AIDS Conference*. Munich, Germany. July 22-26, 2024.
10. Salusso D, Gun A, Nava A, Garcia J, Abba M, Salas ME, Delgado P, Golemba M, Moragas M, Naipauer J, Perez C, Cesar C, Cahn P, Figueroa MI, Fink V. Prevalence of High-risk Penile Human Papillomavirus in Men who have Sex with Men and Transgender Women. Oral presentation (OAB0103). *AIDS 2024, the 25th International AIDS Conference*. Munich, Germany. July 22-26, 2024.
11. Bhatta MR, Selvan ME, Spyrou N, Nathan DI, Gumus ZH, Marcellino B, Sigel K. Description of Clonal Hematopoiesis in a Hospital-based Cohort of People living with HIV. Poster Presentation, Abstract #751. *Conference on Retroviruses and Opportunistic Infections (CROI)*. Denver, CO. March 3-6, 2024.
12. Kamel R, Kang M, Moser C, Ambinder R, Dittmer D, Hosey L, Matining R, Hosseinipour M, Borok M, Campbell T, Krown S, Macatangay B, Rinaldo C. Baseline KSHV T Cell Responses are Associated with Pre-Treatment Clinical Presentation in KS. Abstract #750. *Conference on Retroviruses and Opportunistic Infections (CROI)*. Denver, CO. March 3-6, 2024. **[AMC-066/067]**

### 2023

13. Bender Ignacio R, Phipps W, Kwon D, Okuku F, Burger R, Ambinder R, Gantt S, for the AMC-098 Team. A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma: AMC 098, A Trial of the AIDS Malignancy Consortium. Oral and Poster presentation. *Biennial AORTIC (African Organisation for Research and Training in Cancer) International Conference on Cancer in Africa*. Senegal, Africa. November 3-6, 2023. **[AMC-098]**
14. Gubser C, Chiu C, Schroeder J, Rajdev L, Tumpach C, Pascoe RD, Durand C, Chang J, Solomon A, Cao R, Martelotto L, Bethony J, Utzschneider D, Kallies A, Davenport M, Speed T, Anderson J,



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

Rasmussen TA, Lewin SR. Favourable Transcriptomic Signature of HIV-specific CD8 T Cells in Response to Single Anti-PD1 dose in People with HIV on ART and Cancer. *12th IAS (International AIDS Society) Conference on HIV Science*. Brisbane, Australia. July 23-26, 2023. **[AMC-095]**

15. Matsikidze E, Ndlovu N, Makunike-Mutasa R, Chirenje ZM, Borok M, Mazhindu TA, Magande P, Mandishora RS, and Palefsky JM. Human Papilloma Virus Genotype Distribution in Vulvar Cancer in Zimbabwe, [AMC fellow awardee 2018-2020]. Poster presentation, *35th International Papilloma Virus Conference (IPVC 2023)*. Washington, D.C. April 17-21, 2023.
16. Stier E. Anal Histologic High-Grade Squamous Intraepithelial Lesions (hHSIL) In Women Living with HIV (WLHIV)--2 Year Outcomes and Screening Implications: AIDS Malignancy Consortium (AMC) 084]. *35th International Papillomavirus Conference (IPVC 2023)*. Washington, D.C. April 17-21, 2023. **[AMC-084]**
17. Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed EH, Pearson R, Kitzler R, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal AM, Krishnan A, Wachsman W, Williams N, Sharma N, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Malvestutto C, Choe H, Behbehani G, Lozanski G, Blaser B, and Baiocchi RA. Update on Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. Oral presentation. *2023 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR*. Orlando, FL. February 15-19, 2023. **[AMC-080 and AMC-071]**

### **2022**

18. Barta SK, Noy A, Pasquini MC, He N, Hunt T, Litovich C, Ibrahim U, Baiocchi RA, Ambinder RF. Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies - Interim Results of AIDS Malignancy Consortium (AMC) Study **AMC-113**. Abstract. *Blood*. 2022; 140 (Supplement 1): 1847-1848. doi: <https://doi.org/10.1182/blood-2022-165370>
19. Epstein-Peterson Z. Trial-in-Progress: AMC-112: Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma (NCT05077527). *64th American Society of Hematology (ASH) Annual Meeting*. Virtual. December 10-13, 2022. **[AMC-112]**
20. Epeldegui M, Chang D, Lee JY, Borok M, Bukuru A, Busakhala N, Hosseinipour M, Kang M, Kanyama C, Langat D, Mngqibisa R, Mwelase N, Nyirenda M, Samaneka W, Hoagland B, Campbell TB, Martinez-Maza O, Krown SE. Association of Serum Biomarkers with Clinical Response of Limited-Stage AIDS/KS in Resource-Limited Settings: Results from the ACTG A5264/AMC-067 Clinical Trial. *International Conference on Malignancies in HIV/AIDS*. Virtual. October 24-26, 2022. **[AMC-067]**
21. Salusso D, Gun A, Abba M, Fink V. Penile Human Papillomavirus (HPV) in Men who have Sex with Men (MSM) and Transgender Women (TGW) from Buenos Aires: Initial Experience and Sample



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

Collection Set-up. Oral presentation in the Junior Investigator Research In-Progress Session. *International Conference on Malignancies in HIV/AIDS*. Virtual. October 24-26, 2022.

22. Abou-Alfa GK, Afihene M, Capanu M, Li Y, Chou JF, Asombang A, Alatise OI, Bounedjar A, Cunha L, Mekonnen HD, Diop PS, Elwakil R, Ali MM, Ndlovu N, Ndumbalo J, Makondi PT, Tzeuton C, Biachi de Castria T, Agyei-Nkansah AA, Balogun F, Bougouma A, Atipo Ibara BI, Jonas E, Kimani S, Kingham P, Kurrimbukus R, Hammad N, Fouad M, El Baghdady N, Servais Albert Fiacre EB, Sewram V, Spearman CW, Yang JD, Roberts LR, Abdelaziz AO. Africa Guidelines for Hepatocellular Carcinoma (HCC) Build-Up Process. *Conference on Liver Disease in Africa (COLDA) 2022*. Cape Town, South Africa. September 29-October 1, 2022.
23. Epeldegui Epeldegui M, Chang D, Lee JY, Borok M, Bukuru A, Busakhala N, Campbell TB, Hosseiniipour M, Kang M, Kanyama C, Langat D, MacRae J, Martin J, Mngqibisa R, Mwelase N, Nyirenda M, Orem J, Samaneka W, Hoagland B Martinez-Maza O, Krown SE. Predictive value of serum biomarkers for clinical responses of mild-to-moderate AIDS-KS in resource-limited settings. *International KSHV & Related Agents Meeting*. Virtual. July 10-13, 2022.

### 2021

24. Stier E. A., editor. Risks Factors for Incidental Anal Histologic High-Grade Squamous Intraepithelial (hHSIL) in Women Living with HIV (WLHIV): AIDS Malignancy Consortium (AMC) 084. International Papillomavirus Conference; 2021. November 15-19, 2021 **[AMC-084]**
25. Abou-Alfa GK, Afihene M, Capanu M, Li Y, Chou JF, Asombang A, Alatise OI, Bounedjar A, Cunha L, Mekonnen HD, Diop PS, Elwakil R, Ali MM, Ndlovu N, Ndumbalo J, Makondi PT, Tzeuton C, Biachi de Castria T, Agyei-Nkansah AA, Balogun F, Bougouma A, Atipo Ibara BI, Jonas E, Kimani S, Kingham P, Kurrimbukus R, Hammad N, Fouad M, El Baghdady N, Servais Albert Fiacre EB, Sewram V, Spearman CW, Yang JD, Roberts LR, Abdelaziz AO. Africa Guidelines for Hepatocellular Carcinoma (HCC) Build-Up Process. *13th African Organization for Research and Training in Cancer (AORTIC) Virtual Meeting*. November 5-10, 2021.
26. Shindiapina P., editor. Update on Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. European Congress of Immunology; 2021 September 1-4, 2021; Virtual. **[AMC-071; AMC-080]**
27. Morales A, Genovese C, Bott M, Alvarez J, Mun SS, Totonchy J, Gautam A, Delgado de la Mora J, Chang S, Ibáñez de Garayo M, Wirth D, Horenstein M, Dao T, Scheinberg DA, Rubinstein PG, Semeere A, Martin J, Borok M, Campbell TB, Krown SE, Cesarman E. WT1 Tumor Antigen is Overexpressed in Kaposi Sarcoma and is Regulated by KSHV vFLIP. *International KSHV & Related Agents Meeting*. Virtual. June 21-24, 2021. **[AMC-066]**

### 2020

28. Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed E, Pearson R, Kitzler R, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal AM, Krishnan A, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Behbehani G, Lozanski G, Baiocchi RA. Comparative



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

Analysis of Immune Reconstitution in HIV-positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT-CTN-0903/AMC-080 and BMT-CTN-0803/AMC-071 Trials. 61st American Society of Hematology (ASH) Annual Meeting; 2020 December 7-10; Orlando, FL. [\[AMC-071; AMC-080\]](#)

29. Bakari S, Botello-Harbaum M, Tholanah M, Rappoport C, Aboulafia D. A Global Community Advisory Board (GCAB) to Enhance Clinical Research Studies in the AIDS Malignancy Consortium (AMC). *2020 Summit on National and Global Cancer Health Disparities (SCHD)*. Seattle, WA. April 3-4, 2020.
30. Ellsworth GB, Lensing SY, Stier EA, Chiao EY, Darragh T, Palefsky JM, Wilkin TJ. Xpert HPV as an Improved Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions (hHSIL) in Women Living with HIV (WLHIV). *33rd International Papillomavirus Conference (IPVC)*. Barcelona, Spain. March 23-27, 2020. [\[AMC-084\]](#)
31. Palefsky J, Lensing S, Belzer M, Lee J, Gaur A, Mayer K, Futterman D, Stier E, Paul M, Chiao E, Reirden D, Goldstone S, Cachay E, Ortiz A, Barroso L, Da Costa M, Wilson C, Kahn J. AMC-072: 24-Month Efficacy of the Quadrivalent HPV Vaccine Against Anal High-Grade Squamous Intraepithelial Lesions in HIV-Positive Men Who Have Sex with Men Aged 18-26 Years. Oral presentation. *33rd International Papillomavirus Conference (IPVC)*. Barcelona, Spain. March 23-27, 2020. [\[AMC-072\]](#)
32. Stier EA, Lensing SY, Wiley DJ, Darragh T, Palefsky JM, Chiao EY. Screening Strategies for Anal histologic High-Grade Squamous Intraepithelial Lesion (hHSIL) Detection in Women Living with HIV (WLHIV) – AIDS Malignancy Consortium (AMC)-084. *33rd International Papillomavirus Conference (IPVC)*. Barcelona, Spain. March 23-27, 2020. [\[AMC-084\]](#)
33. Anderson J, Abedi M, Asmuth DM, Esteghamat N, Luxardi G, Wieduwilt M, Pollard R, Kaplan L, Lee J, Noy A, Beegle J, Maciel H. Early Safety Data of a Phase I Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells. *Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT Meetings)*. Orlando, FL. February 19-23, 2020. [\[AMC-097\]](#)
34. Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed E, Pearson R, Kitzler R, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal AM, Krishnan A, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Behbehani G, Lozanski G, Baiocchi RA. Comparative Analysis of Immune Reconstitution in HIV-positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT-CTN-0903/AMC-080 and BMT-CTN-0803/AMC-071 Trials. Poster presentation. *Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR*. Orlando, FL. February 19-23, 2020. [\[AMC-080 / AMC-071\]](#)

**2019**

35. Ramos JC, Lee JY, Kaplan LD, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R, Sparano JA. Response-Adapted Therapy with Infusional EPOCH Chemotherapy plus Rituximab in HIV-Associated, B-cell Non-Hodgkin's



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

Lymphoma. Poster presentation. *61st American Society of Hematology (ASH) Annual Meeting*. Orlando, FL. December 7-10, 2019. [\[AMC-034\]](#)

36. Ramos JC, Sparano JA, Moore PC, Siegel E, Lee JY, Reid EG, Ambinder RF, Chadburn A, Rubinstein PG, Durand CM, Cesarman E, Ratner L, Baiocchi R, Aboulafia D, Kaplan L, Henry DH, Capoferri AA, Mitsuyasu R, Noy A, and the AIDS Malignancy Consortium (AMC). A Randomized Trial of EPOCH-based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes. Poster presentation. *61st American Society of Hematology (ASH) Annual Meeting*. Orlando, FL. December 7-10, 2019. [\[AMC-075\]](#)
37. Rubinstein PG, Moore PC, Bimali M, Chadburn A, Cesarman E, Rudek M, Ratner L, Ambinder RF, Henry DH, Barta SK, Salles G, Coppo P, Delobel P, Boué F, Oksenhendler E, Ramos JC, Reid EG, Sharon E, Mounier N, Besson C, Noy A. Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085. Oral presentation. *61st American Society of Hematology (ASH) Annual Meeting*. Orlando, FL. December 7-10, 2019. [\[AMC-085\]](#)
38. Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed E, Pearson R, Kitzler R, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal AM, Krishnan A, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Behbehani G, Lozanski G, Baiocchi RA. Comparative Analysis of Immune Reconstitution in HIV-positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT-CTN-0903/AMC-080 and BMT-CTN-0803/AMC-071 Trials. Poster presentation. *61st American Society of Hematology (ASH) Annual Meeting*. Orlando, FL. December 7-10, 2019. [\[AMC-080 / AMC-071\]](#)
39. Adams SV, Samaneka W, Puronen C, Mwelase T, Orem J, Krown S, Hosseinipour M, Campbell T, Uldrick TS. Suspected KSHV Inflammatory Cytokine Syndrome (KICS) in Participants with Mild or Moderate AIDS-KS Enrolled in A5264/AMC067 is Associated with Inferior Survival. Oral presentation. *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 21-22, 2019. [\[AMC-067\]](#)
40. Chiao E, Wiley DJ, Lensing SY, Darragh T, Einstein MH, Jay N, Berry Lawhorn JM, Deshmukh AA, Palefsky JM, Wilkin T, Barroso LF, Levine R, French AL, Guiot H, Cranston RD, Stier E. Screening Tests for Anal High-Grade Squamous Intraepithelial Lesion Detection in Women Living with HIV. *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 21-22, 2019. [\[AMC-084\]](#)
41. Krown S, Moser C, MacPhail P, Matining R, Godfrey C, Caruso S, Hosseinipour MC, Samaneka W, Nyirenda M, Busakhala N, Okuku F, Kosgei J, Hoagland B, Mwelase N, Oliver V, Burger H, Mngqibisa R, Nokta M, Campbell T, and Borok M, for the A5263/AMC066 Team. Treatment of Advanced AIDS-associated Kaposi Sarcoma (AIDS-KS) in Resource-Limited Settings: A Three-Arm, Open-Label, Randomized, Non-Inferiority Trial in Five sub-Saharan African (SSA) Countries and Brazil (ACTG A5263/AMC066). *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 21-22, 2019. [\[AMC-066\]](#)



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

42. Lee J, Botello-Harbaum MT, Medina R, Lensing S, Zozus M. Assessing Clinical Trial Self-Perceived Competence Among International Sites Participating in the AIDS Malignancy Consortium. *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 21-22, 2019.
43. Lee J, Lensing S, Berry JM, Palefsky J. Challenges of Recruiting HIV+ Participants to a Cancer Prevention Trial. *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 21-22, 2019. **[ANCHOR]**
44. Marcelo Horenstein, Elizabeth Margolskee, Julio Alvarez, Ayana Morales, Robert Coombs, Catherine Godfrey, Thomas Campbell, Margaret Borok-Williams, Susan Krown, Ethel Cesarman. Evaluating Kaposi's sarcoma histopathology, host immune response, and KSHV latent and lytic activity in biopsies from the multinational trial AMC-066/A5263. *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 21-22, 2019.
45. Martinez-Maza O, Lee J, Chang D, Lensing S, Mitsuyasu R, Sparano J, Epeldegui M. Prognostic Biomarkers For AIDS-related non-Hodgkin Lymphoma: Measurement of Biomarkers of Microbial Translocation in the AMC-034 study. Poster presentation. *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 21-22, 2019. **[AMC-034]**
46. Morales A, Krown S, Boroks M, Campbell T, Rubinstein P, Martin J, Semeere A, Phipps W, Alvarez J, Chang S, Cesarman E. The Role of Wilms' Tumor 1 (WT1) in Kaposi Sarcoma Herpesvirus Oncogenesis. *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 21-22, 2019. **[AMC-066]**
47. Ngongondo M, Nyirenda M, Kang M, Umbleja T, Krown SE, Godfrey C, Samaneka W, Mngqibisa R, Hoagland B, Mwelase N, Caruso S, Martinez-Maza O, Dittmer DP, Borok M, Hosseinipour MC, Campbell TB, for the A5264/AMC-067 Team. Early Progression and Immune Reconstitution Inflammatory Syndrome during Treatment of Mild-to-Moderate Kaposi Sarcoma in Low-Resource Settings: Incidence, Long-Term Outcomes and Effects of Early Chemotherapy. *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 21-22, 2019. **[AMC-067]**
48. Rajdev L, Lensing S, Ramos JC, Baiocchi R, Wang C, Ratner L, Rubinstein PG, Ambinder R, Henry D, Streicher H, Little RF, Chiao E, Lee M, Dittmer DP, Einstein MH, Sparano JA, Mitsuyasu R, AIDS Malignancy Consortium. AMC-095: A Report of Nivolumab (Nivo) in Advanced HIV-associated Solid Tumors (ST). *European Society for Medical Oncology Congress (ESMO)*. Madrid, Spain. September 18-22, 2020. **[AMC-095]**
49. Lee J, Lensing S, Botello-Harbaum MT, Medina R, Zozus M. Assessing Clinical Trial Self-Perceived Competence Among International Sites Participating in the AIDS Malignancy Consortium. *Society for Clinical Trials (SCT) 40th Annual Meeting*. New Orleans, LA. May 19-22, 2019.
50. Rasmussen TA, Rajdev L, Chea S, Tennakoon S, Dantanarayana A, Rhodes A, Rigau D, Lensing S, Rutishauser R, Bakkour S, Busch M, Dittmer D, Deeks S, Durand C, Lewin SR. Impact of Anti-PD-1 and Anti-CTLA-4 on the HIV Reservoir In Vivo: The AMC-095 Study. *Conference on Retroviruses and Opportunistic Infections (CROI)*. Boston, MA. March 8-11, 2020. **[AMC-095]**



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

### 2018

51. Goldstone S, Lensing SY, Stier E, Darragh T, Lee J, van Zante A, Jay N, Berry-Lawhorn MJ, Cranston R, Mitsuyasu R, Aboulafia D, Palefsky J, Wilkin T. A Randomized Clinical Trial of Infrared Coagulation Ablation versus Active Monitoring of Intra-anal High-grade Dysplasia in HIV-infected Adults: An AIDS Malignancy Consortium Trial. *32nd International Papillomavirus Conference (IPVC)*. Sydney, Australia. October 2-6, 2018. **[AMC-076]**
52. Borok M, Moser C, Campbell T, MacPhail P, Matining R, Caruso S, Godfrey C, Moses A, Samanek W, Nyirenda M, Busakhala N, Burger H, Mwelase N, Hoagland B, Kosgei J, Orem J, Nokta M, Otieno V, Mngqibisa R, Krown S. Superiority of Paclitaxel compared to either Bleomycin/Vincristine or Etoposide as Initial Chemotherapy for Advanced AIDS-KS in Resource-limited Settings: A Multinational Randomized Trial of the ACTG and the AIDS Malignancy Consortium. Abstract THAB0108LB; *AIDS 2018, 22nd International AIDS Conference*; Amsterdam, the Netherlands. Volume 21, Issue S6, pp. 165-166; *Journal of the International AIDS Society. Special Issue: Oral abstracts of the 22nd International AIDS Conference*, Amsterdam, the Netherlands. July 23-27, 2018; e2514. **[AMC-066]**
53. Haigentz M, Moore P, Ratner L, Henry D, Rubinstein P, Ramos JC, Rudek M, Eng Y, Cooley T, Deeken J, Little R, Sparano JA, Mitsuyasu R, AIDS Malignancy Consortium. Tolerability of Paclitaxel/Carboplatin (PCb) in Solid Tumor Patients with HIV Infection. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. June 1-5, 2018.
54. Ramos JC, Sparano JA, Moore PC, Cesarman E, Reid EG, Rubinstein P, Harrington RD, Baiocchi R, Aboulafia D, Ratner L, Kaplan L, Durand C, Ambinder RF, Lee JY, Mitsuyasu RT, Noy A, and AIDS Malignancy Consortium. AMC-075: A Randomized Phase II Trial of Vorinostat with R-EPOCH in Aggressive HIV-related B-cell Non-Hodgkin's Lymphomas (NHL). *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. June 1-5, 2018. **[AMC-075]**
55. Lensing S, Lee JY, Berry JM, Palefsky J. Challenges and Successes in Recruitment of HIV Infected Persons to a Cancer Prevention Study. *Annual Meeting of the Society of Clinical Trials (SCT)*, Portland, OR. May 20-23, 2018. **[ANCHOR]**
56. Einstein MH, Ndlovu N, Lee JY, Palefsky JM, Kotzen J, Garg M, Whitney K, Stier E, Mitsuyasu R, Krown S. Cisplatin and Radiation Therapy in HIV-infected Women with Locally Advanced Cervical Cancer in Sub-Saharan Africa (SSA). *Society of Gynecologic Oncology (SGO) 49th Annual Meeting on Women's Cancer*. New Orleans, LA. March 23, 2018.
57. Campbell TB, Kang M, Umbleja T, Krown SE, Bukuru A, Martin J, Godfrey C, Nyirenda M, Busakhala N, Borok M, Langat D, Hoagland B, Mwelase N, Hosseinipour MC, A5264/AMC-067 REACT-KS Team. Predictors of KS-IRIS in Mild/Moderate AIDS-KS during ART in Low-resource Settings. *Conference on Retroviruses and Opportunistic Infections (CROI)*. Boston, MA. March 4-7, 2018. **[AMC-067]**
58. Rajdev L, Chiao L, Lensing S, Streicher H, Little RF, Dittmer DP, Einstein MH, Haigentz M, Sparano JA, Mitsuyasu R. A Phase I Study of Ipilimumab (IPI) and Nivolumab (NIVO) in Advanced HIV Associated Solid Tumors (ST) with Expansion Cohorts in HIV Associated Solid



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

Tumors and Classical Hodgkin Lymphoma (cHL). *American Society of Clinical Oncology (ASCO)-Society for Immunotherapy of Cancer (SITC)*. San Francisco, CA. January 25-27, 2018. [\[AMC-095\]](#)

### 2017

59. Rajdev L, Haigentz M, Lensing S, Streicher H, Little RF, Dittmer DP, Einstein MH, Chiao E, Sparano JA, Mitsuyasu R. A Phase I Study of Ipilimumab (Ipi) and Nivolumab (Nivo) in Advanced HIV Associated Solid Tumors (Preliminary Findings). *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 23-24, 2017. [\[AMC-095\]](#)
60. Reid E, Suazo A, Lensing S, Dittmer D, Ambinder R, Maldarelli F, and Wachsman W on behalf of the AIDS Malignancy Consortium (AMC). Pilot Study of Bortezomib Exploiting an Oncolytic Viral Strategy in AIDS-associated Kaposi Sarcoma. Poster presentation. *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 23-24, 2017. [\[AMC-063\]](#)
61. Ely S, Gardner A, Margolskee E, Bukuru A, Martin J, Campbell T, Hosseinipour M, Krown S, Godfrey C, Coombs R, Cesarman C. Patient Biopsies from the Multinational Kaposi's Sarcoma Trial A5264/AMC067 Show Broad Variability in the Percentage of LANA+ cells and Only Rare Lytic Reactivation. Poster presentation. *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 23-24, 2017. [\[AMC-067\]](#)
62. Shimabukuro K, Moore P, Bui J, Dittmer D, Ambinder R, Martinez-Maza O, and Reid E for the AIDS Malignancy Consortium (AMC). Lenalidomide is Safe and Effective in AIDS-associated Kaposi Sarcoma. Oral presentation. *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 23-24, 2017. [\[AMC-070\]](#)
63. Rajdev L, Chiao L, Lensing S, Streicher H, Little RF, Dittmer DP, Einstein MH, Haigentz M, Sparano JA, Mitsuyasu R. A Phase I Study of Ipilimumab (Ipi) and Nivolumab (Nivo) in Advanced HIV Associated Solid Tumors (ST) with Expansion Cohorts in HIV Associated Solid Tumors and Classical Hodgkin Lymphoma (cHL). *International Conference on Malignancies in HIV/AIDS (ICMH)*. Bethesda, MD. October 23-24, 2017. [\[AMC-095\]](#)
64. Burkhalter JE, Aboulafia DM, Botello-Harbaum M, Lee JY. Participant Characteristics and Clinical Trial Decision-making Factors in AIDS Malignancy Consortium Treatment Trials for HIV-infected Persons with Cancer. *Society of Clinical Research Associates (SOCRA) Conference*. Orlando, FL. October 6-8, 2017. [\[AMC-S006\]](#)
65. Ely S, Gardner A, Umbleja T, Bukuru A, Martin J, Campbell T, Hosseinipour M, Krown S, Godfrey C, Coombs R, Cesarman E. Patient Biopsies from the Multinational Kaposi's Sarcoma Trial A5264/AMC062 Show Broad Variability in the Percentage of LANA+ Cells and only Rare Lytic Reactivation. Oral presentation. *20<sup>th</sup> International Workshop on Kaposi's Sarcoma Herpes Virus (KSHV) and Related Agents*. Berlin, Germany. July 25-28, 2017. [\[AMC-062\]](#)
66. Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin J, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok-Williams M, Samanekwa W, Moses A, Martinez-Maza O, Ambinder R, Dittmer D, Nokta M, Campbell T, A5264/AMC-067



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

REACT-KS Team. Immediate vs. Delayed Oral Etoposide (ET) among HIV-infected Individuals with Limited-stage KS Initiating ART: A5264/AMC-067 study. *9<sup>th</sup> IAS Conference on HIV Science*. Paris, France. July 23-26, 2017. **[AMC-067]**

67. Haigentz Jr. M, Moore PC, Ratner L, Henry DH, Rubinstein PG, Ramos JC, Rudek MA, Eng Y, Cooley TP, Deeken JF, Little RF, Mitsuyasu RT, AIDS Malignancy Consortium. Tolerability of Paclitaxel/Carboplatin (PCb) in Solid Tumor Patients (pts) Infected with HIV (AMC-078). *2017 American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. June 2-6, 2017. Publication-only abstract. *Journal of Clinical Oncology* 35. 2017. (suppl; abstr e14077). **[AMC-078]**
68. Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC. Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies in HIV Patients: Results of the BMT CTN 0903 / AMC-080 Trial. *2017 American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. June 2-6, 2017. **[AMC-080]**
69. Stier EA, Lee JY, Lensing S, Jay N, Berry-Lawhorn JM, Einstein M, Palefsky J, Wilkin T, Goldstone S, Chiao E. Anal High-Grade Squamous Intraepithelial Lesions (HSIL) In HIV Positive (HIV+) Women, Prevalence and Risk Factors: AIDS Malignancy Consortium (AMC) 084. Oral presentation. *IFCPC 2017 World Congress for Cervical Pathology and Colposcopy*. Orlando, FL. April 4-7, 2017. **[AMC-084]**
70. Chiao E, Wiley DJ, Lee J, Deshmukh AA, Cantor SB, Palefsky J, Stier E. Multiple-test Anal Cancer Screening Strategies Improve Anal HSIL-detection in HIV+ Women. Poster presentation, #248. *HPV 2017: 31<sup>st</sup> International Papillomavirus Conference*. Cape Town, South Africa. February 28-March 4, 2017.
71. Deshmukh AA, Stier EA, Lensing S, Wiley D, Cantor SB, Palefsky JM, Chiao EY. Age-Specific Prevalence of Anal and Cervical HPV, and Anal Cytology and Histology in HIV-positive Women. *HPV 2017: 31<sup>st</sup> International Papillomavirus Conference*. Cape Town, South Africa. February 28-March 4, 2017.
72. Einstein MH, Ndlovu N, Lee JY, Palefsky JM, Kotzen J, Garg M, Whitney K, Stier E, Mitsuyasu R, Krown S. Cisplatin and Radiation Therapy in HIV-infected Women with Locally Advanced Cervical Cancer in Sub-Saharan Africa (SSA). *HPV 2017: 31<sup>st</sup> International Papillomavirus Conference*. Cape Town, South Africa. February 28-March 4, 2017.
73. Goldstone SE, Stier EA, Lensing S, Jay N, Berry M, Cranston R, Darragh T, Lee J, Aboulafia D, van Zante A, Mitsuyasu R, Palefsky JM, Wilkin T. Infrared Coagulation (IRC) Ablation versus Deferred Treatment of Intra-Anal High-grade Squamous Intraepithelial Lesions (HSIL) in HIV-infected Subjects: AIDS Malignancy Consortium 076. *HPV 2017: 31<sup>st</sup> International Papillomavirus Conference*. Cape Town, South Africa. February 28-March 4, 2017.
74. Kahn J, Lee J, Rudy B, Belzer M, Palefsky JM. Most HIV-Infected Young Men Demonstrate Appropriate Risk Perceptions and Beliefs About Safer Sexual Behaviors After Human



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

Papillomavirus Vaccination. *HPV 2017: 31<sup>st</sup> International Papillomavirus Conference*. Cape Town, South Africa. February 28-March 4, 2017.

75. Palefsky JM. Incidence of Cervical HPV Infection After Quadrivalent HPV (qHPV) Vaccination in HIV-infected Women. *HPV 2017: 31<sup>st</sup> International Papillomavirus Conference*. Cape Town, South Africa. February 28-March 4, 2017.
76. Palefsky JM, Belzer M, Rudy B, Lee J, Kahn JA. Pre-vaccination Exposure to HPV Vaccine Types in 13 to 26-year-old HIV-Positive Men Who Have Sex with Men. *HPV 2017: 31<sup>st</sup> International Papillomavirus Conference*. Cape Town, South Africa. February 28-March 4, 2017.
77. Stier EA, Lee JY, Lensing S, Jay N, Jay N, Berry-Lawhorn JM, Einstein M, Palefsky J, Wilkin T, Goldstone S, Chiao E. Anal High-Grade Squamous Intraepithelial Lesions (HSIL) In HIV Positive (HIV+) Women, Prevalence and Risk Factors: AIDS Malignancy Consortium (AMC) 084. Oral presentation. *HPV 2017: 31<sup>st</sup> International Papillomavirus Conference*. Cape Town, South Africa. February 28-March 4, 2017. **[AMC-084]**
78. Wiley DJ, Chiao E, Lee J, Deshmukh AA, Cantor SB, Palefsky J, Stier E. Multiple-test Anal Cancer Screening Strategies Improve Anal HSIL-detection in HIV+ Women. *Conference on Retroviruses and Opportunistic Infections (CROI)*. Seattle, WA. February 13-16, 2017.

### 2016

79. Reid E, Looney D, Maldarelli F, Noy A, Henry DH, Aboulafia DM, Ramos JC, Sparano J, Ambinder RF, Lee J, Mitsuyasu RT, Wachsman W. AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas. *58<sup>th</sup> American Society of Hematology (ASH) Annual Meeting & Exposition*. San Francisco, CA. December 3-6, 2016. **[AMC-053]**
80. Atkinson T, Webb A, Shuk E, Palefsky J, Berry JM, Goldstone S, Barrera-Vera R, Levine R, Wilkin T, Bucher G, Cella D, Lee J, Taylor J, Burkhalter J. Development of a Health-related Quality of Life Symptom Index for Persons Diagnosed with and either Treated or Monitored for Anal HSIL (AMC-A02, -A03). *International Anal Neoplasia Society (IANS) Scientific Meeting*. San Francisco, CA. November 11-13, 2016. **[AMC-A02, -03]** **[ANCHOR]**
81. Deshmukh AA, Stier EA, Lensing S, Wiley D, Cantor SB, Palefsky JM, Chiao EY. Age-Specific Prevalence of Anal and Cervical HPV, and Anal Cytology and Histology in HIV-positive Women. *International Anal Neoplasia Society (IANS) Scientific Meeting*. San Francisco, CA. November 11-13, 2016. **[AMC-084]**
82. Goldstone S. Infrared Coagulation Ablation vs. Deferred Treatment of Intra-anal HSIL in HIV-infected Subjects: AIDS Malignancy Consortium 076. *International Anal Neoplasia Society (IANS) Scientific Meeting*. San Francisco, CA. November 11-13, 2016. **[AMC-076]**
83. Palefsky JM, Isaacson Wechsler E, Tugizov S, Herrera R, Da Costa M. E5 is Expressed in Anal Cancer and Leads to EGFR-Induced Invasion in Human Papillomavirus 16-Transformed Anal Epithelial Cells. *International Anal Neoplasia Society (IANS) Scientific Meeting*. San Francisco, CA. November 11-13, 2016. **[AMC-045]**



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

84. Stier EA, Lee JY, Lensing S, Jay N, Jay N, Berry-Lawhorn JM, Einstein M, Palefsky J, Wilkin T, Goldstone S, Chiao E. Anal High-Grade Squamous Intraepithelial Lesions (HSIL) In HIV Positive (HIV+) Women, Prevalence and Risk Factors: AIDS Malignancy Consortium (AMC) 084. *International Anal Neoplasia Society (IANS) Scientific Meeting*. San Francisco, CA. November 11-13, 2016. **[AMC-084]**
85. Wiley D. Associations between Anal Group 1 High-Risk HPV Infections and Serum Cytokines, Chemokines, and Free Testosterone. *International Anal Neoplasia Society (IANS) Scientific Meeting*. San Francisco, CA. November 11-13, 2016.
86. Wiley DJ, Chiao E, Lee J, Deshmukh AA, Cantor SB, Palefsky J, Stier E. Multiple-test Anal Cancer Screening Strategies Improve Anal HSIL Detection in HIV-positive Women and MSM: A Report of Two Trials. *International Anal Neoplasia Society (IANS) Scientific Meeting*. San Francisco, CA. November 11-13, 2016. **[AMC-084]**
87. Atkinson TM, Shuk E, Palefsky J, Berry-Lawhorn JM, Goldstone SE, Barrera-Vera RJ, Einstein M, Levine R, Wilkin TJ, Bucher G, Cella D, Lee J, Taylor J, Burkhalter J. Initial Development and Content Validation of a Health-related Quality of Life Symptom Index for Persons Diagnosed with and either Treated or Monitored for Anal High-grade Squamous Intraepithelial Lesions (HSIL). *23<sup>rd</sup> Annual Conference of the International Society of Quality of Life Research*. Copenhagen, Denmark. October 19-22, 2016. **[ANCHOR]**
88. Goldstone SE, Stier E, Lensing S, Jay N, Berry M, Cranston R, Darragh T, Lee J, Aboulafia D, van Zante A, Mitsuyasu R, Palefsky JM, Wilkin T. AMC-076: An AIDS Malignancy Consortium Randomized Clinical Trial of Infrared Coagulation (IRC) Ablation versus Deferred Treatment of Intra-Anal High Grade Squamous Intraepithelial Lesions (HSIL) in HIV-infected Subjects: Preliminary Results. *21st International AIDS Conference*. Durban, South Africa. July 18-22, 2016. **[AMC-076]**
89. Selvamuthu P, Palefsky J. Incidence and Persistence of Cervical HPV Infection after Quadrivalent HPV (qHPV) Vaccination in HIV-infected Women. *21st International AIDS Conference*. Durban, South Africa. July 18-22, 2016.
90. Lee J, Burkhalter J, Botello-Harbaum M, Aboulafia D. Clinical Trial Participation Among HIV-infected Persons with Cancer. *Society for Clinical Trials 37th Annual Meeting*. Montreal, Quebec, Canada. May 15-18, 2016.

### **2015**

91. Petrowski KA, Poola H, Chuy KL, Gupta S, and Rubinstein PG. AIDS-Related vs. Non-AIDS-Related Diffuse Large B-Cell Lymphoma. Analysis of the County Hospital AIDS Malignancy Project (CHAMP). *American Society of Hematology (ASH) Meeting*. Orlando, FL, December 5-8, 2015.
92. Rubinstein PG, Moffitt AB, Petrowski KA, Messinger M, Davis N, Love C, Dave S, Chadburn A. The Landscape of microRNA Expression in HIV and Non-HIV Associated Classical Hodgkin Lymphoma through Next Generation Sequencing. *American Society of Hematology (ASH) Meeting*. Orlando, FL. December 5-8, 2015.



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

93. Rubinstein PG, Moore P, Henry DH, Ratner L, Sharon E, Noy A. AMC-085: A Pilot Trial of AVD and Brentuximab Vedotin in the Upfront Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma. A Trial of the AIDS Malignancy Consortium. *American Society of Hematology (ASH) Meeting*. Orlando, FL. December 5-8, 2015. [\[AMC-085\]](#)
94. Bender Ignacio RA, Lee JY, Rudek MA, Dittmer DP, Ambinder RF, Krown SE. A Phase 1b/Pharmacokinetic Trial of PTC299, A Novel Post-transcriptional VEGF Inhibitor, for AIDS-related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. *15<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)*. Bethesda, MD. October 26-27, 2015. [\[AMC-059\]](#)
95. Chiao E, Rudek MA, Moore PC, Aboulafia DM, Ambinder RF, Baiocchi R, Shimabukuro KA, Brody VC, Chuy JW, Lee JY, Little RF, Mitsuyasu RT, Haigentz Jr M. AMC-087: Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection. *15<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)*. Bethesda, MD. October 26-27, 2015. [\[AMC-087\]](#)
96. Ely S, Barouk S, Gapara M, Lammersen K, Darden J, Borok M, Hosseinipour MC, Krown S, Campbell T, Wetherall N, Coombs RW, Cesarman E, Godfrey C. Pathology External Quality Assurance Program for Kaposi's Sarcoma International Clinical Trials AMC-067/A5264 and AMC-066/A5263. *15<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)*. Bethesda, MD. October 26-27, 2015. [\[AMC-066 and AMC-067\]](#)
97. Pareek V, Shcherba M, Hosgood HD, Ginsberg M, Fisher L, Wilson K, Chung J, Hanna DB, Felsen UR, Lin J, Xue X, Spivack S, Keller SM, Anastos K, Strickler HD, Haigentz M Jr. Characteristics of HIV+ Lung Cancer Patients Undergoing Surgical Resection at an Urban Center with High HIV Prevalence: Implications for Lung Cancer Screening. *15<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)*. Bethesda, MD. October 26-27, 2015.
98. Rubinstein PG, Moore P, Henry DH, Ratner L, Sharon E, Noy A. AMC-085: A Pilot Trial of AVD and Brentuximab Vedotin in the Upfront Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma. A Trial of the AIDS Malignancy Consortium. *15<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)*. Bethesda, MD. October 26-27, 2015. [\[AMC-085\]](#)
99. Sheon N, Free Range Studios, the ANCHOR Recruitment and Retention Committee, Community Advisory Board, Palefsky J. Overcoming Stigma to Prevent Anal Cancer among HIV Positive Men and Women in the U.S. (AMC-A01). Poster presentation. *12<sup>th</sup> International AIDS IMPACT Conference*. Amsterdam, Netherlands. July 28-31, 2015. [\[ANCHOR\]](#)
100. Lensing S, Dhakal IB, Reid E, Wong-Sefidan I, Lee JY. Two Stage Phase II Design without Suspending Accrual for Interim Analysis. *Annual Meeting of the Society of Clinical Trials (SCT)*. Arlington, VA. May 17-20, 2015.



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

101. Lensing S, Wong-Sefidan I, Reid E, Lee JY. Two-Stage Phase II Design for Simultaneously Evaluating Efficacy and Toxicity of an Anti-Angiogenic Agent for Treating Kaposi Sarcoma. *Annual Meeting of the Society of Clinical Trials (SCT)*. Arlington, VA. May 17-20, 2015.

### **2014**

102. Ramos JC, Sparano JA, Moore PC, Lee JY, Rudek MA, Ambinder RF, Cesarman E, Noy A, Mitsuyasu RT. AMC-075: The Combination of Vorinostat with Chemotherapy and Rituximab is Tolerable and Feasible in HIV-Related B-cell Non-Hodgkin's Lymphoma with High-risk Features. *American Society of Hematology (ASH) Meeting*. San Francisco, CA. December 6-9, 2014. **[AMC-075]**

103. Wagner-Johnston ND, Lee JY, Silver S, Noy A, Chiao EY, Mims M, Pepin F, Moorhead M, Faham M, Ambinder RF. AMC-064: High Frequency of Identical Lymphoma Clones Detected in Pre-treatment Tumor and Plasma from Untreated Patients with HIV-Associated Lymphomas. *American Society of Hematology (ASH) Meeting*. San Francisco, CA. December 6-9, 2014. **[AMC-064]**

104. Palefsky J, Poongulali S, Lensing S, Lee J, DaCosta M, Jeeva A, Iqbal S, Kumarasamy N. AMC-054: Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Indian HIV-infected Women. *29<sup>th</sup> International Papillomavirus Conference and Clinical & Public Health Workshops*. Seattle, WA. August 21-25, 2014. **[AMC-054]**

105. Raghavendran A, Abraham P, Karthik R, Gnanamony M, Hernandez AL, Subramanian M, Lensing S, Lee JY, Kannangai R, Anand V, Kavi AR, Mathai D, Palefsky JM. AMC-060: Penile Human Papillomavirus Infection in Indian HIV-Positive Men Who Have Sex with Men. *29<sup>th</sup> International Papillomavirus Conference and Clinical & Public Health Workshops*. Seattle, WA. August 21-25, 2014. **[AMC-060]**

106. Shcherba M, Hosgood HD, Lin J, Hanna D, Felsen UR, Ginsberg M, Fisher L, Wilson K, Chung J, Xue X, Anastos K, Piperdi B, Spivack S, Keller SM, Strickler HD, Haigentz M. Characteristics of HIV+ Lung Cancer Cases in a Large Clinical Population: Implications for Lung Cancer Screening. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 1569). Poster presentation, *American Society of Clinical Oncology (ASCO) Annual Meeting*. June 1, 2014.

107. Joshi J, Mounier N, Xue X, Wang D, Ribera JM, Wyen C, Dunleavy K, Little RF, Wilson WH, Noy A, Sparano JA, Barta SK. CNS Involvement in Patients with AIDS-related Lymphomas. Poster presentation, *American Society of Clinical Oncology (ASCO) Annual Meeting*. Abstract Number: 8570 Citation: *Journal of Clinical Oncology*. 32:5s, 2014 (suppl; abstr 8570). Chicago, IL. May 30-June 3, 2014.

108. Palefsky J, Poongulali S, Lensing S, Lee J, DaCosta M, Jeeva A, Iqbal S, Kumarasamy N. AMC-054: Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Indian HIV-infected Women. *Conference on Retroviruses and Opportunistic Infections (CROI)*. Boston, MA. March 3-6, 2014. **[AMC-054]**

109. Wilkin T, Lensing S, Einstein M, Lee J, Goldstone S, Stier EA, Berry M, Jay N, Mitsuyasu R, Palefsky J. Quadrivalent HPV Vaccine Induced Immune Memory in HIV-infected Men.



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

*Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA. March 3-6, 2014.*

### 2013

110. Kanakry JA, Shamay M, Kasamon YL, Li H, Gascoyne RD, Gordon LI, Noy A, Cesarman E, Lee JY, Horning SJ, Ambinder RF. Characterizing the CpG Methylation of Epstein-Barr Virus DNA in the Plasma of Patients with Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma. *American Society of Hematology (ASH) Annual Meeting*. New Orleans, LA. December 7-10, 2013.
111. Noy A, Kaplan L, Lee JY. A Modified Dose Intensive R-CODOX-M/IVAC for HIV-associated Burkitt and Atypical Burkitt-Lymphoma (BL) Demonstrates High Cure Rates and Low Toxicity. Prospective Multicenter Phase II Trial of the AIDS Malignancy Consortium (AMC-048). *American Society of Hematology (ASH) Annual Meeting*. New Orleans, LA. December 7-10, 2013. **[AMC-048]**
112. Ortiz AP, Guiot HM, Díaz-Miranda OL, Román L, Palefsky J, Colón-López V. Recognizing and Treating Anal Cancer: Training Medical Students and Physicians in Puerto Rico. *International Anal Neoplasia Society (IANS) Inaugural Annual Meeting*. San Francisco, CA. November 22-24, 2013.
113. Dittmer DP, Tamurro K, Hosseinipour M, Xiong J, Namarika D, Myirenda M, Mwafongo A, Chiwoko L, Kamwendo D, Hoffman I, Phiri S. Variation in Viral Gene Expression Distinguishes Two Subtypes of Kaposi Sarcoma. *14<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. November 12-13, 2013.
114. Haigentz M, Lin J, Xue X, Ginsberg M, Felsen U, Shcherba M, Hanna D, Fisher L, Chung J, Wilson K, Anastos K, Strickler HD. Characteristics of HIV-Associated Cancer Cases in the Largest Clinical System Serving HIV+ Men and Women in Bronx, NY. Poster presentation. *14<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. November 12-13, 2013.
115. Lee JY, Moore PC, Steliga MA. Comorbidities: Potential Barriers to Enrolling HIV-infected Lung Cancer Cases on Therapeutic Clinical Trials. *14<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. November 12-13, 2013.
116. Shimabukuro K, Moore P, Reid E, Results of a Phase I Study of Lenalidomide in Patients with AIDS-Associated Kaposi Sarcoma (AMC 070). *14<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. November 12-13, 2013. **[AMC-070]**
117. Barta SK, Samuel M, Xue X, Lee JL, Mounier N, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli M, Weiss R, Galicier L, Boue F, Wilson W, Wyen C, Navarro JT, Dunleavy K, Little R, Ratner L, Remick SC, Goldfinger M, Noy A, Sparano JA. A Pooled Analysis of AIDS-related Lymphoma (ARL): An Assessment of Prognostic Factors by Treatment Era. Poster



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

presentation. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. May 31-June 4, 2013.

118. Deeken JF, Mitsuyasu RT, Little RF, Ivy SP, Ambinder RF, Rudek MA, Lee JY, Moore PC, Mosby K, Dezube BJ. Treating HIV+ patients for non-AIDS-defining cancers (NADCs) in the era of targeted chemotherapy: An AIDS malignancy consortium study of sunitinib in patient on ART. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. May 31-June 4, 2013.

### **2012**

119. Shiramizu B, Milne C, Terada K, Cassel K, Matsuno RK, Killeen J, Liang C-Y, Sheeran T, Weihe J, Goodman MT. Community Engagement in Anal Cancer Screening in Hawaii. *13th RCMI International Symposium*. San Juan, Puerto Rico. December 9-13, 2012.

120. Barta SK, Xue X, Wang D, Lee JL, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli M, Boue F, Wilson W, Wyen C, Dunleavy K, Sparano JA. ARL-IPI – A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab-Era. Poster presentation. *American Society of Hematology (ASH) Annual Meeting*. Atlanta, GA. December 8-11, 2012.

121. Barta SK, Xue X, Wang D, Tamrari, R, Mounier N, Lee JL, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli M, Weiss R, Galicier L, Boue F, Wilson W, Wyen C, Navarro JT, Dunleavy K, Little R, Ratner L, Garcia O, Morgades M, Oksenhendler E, Remick SC, Sparano JA. A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors on Clinical Outcomes. Poster presentation. *American Society of Hematology (ASH) Annual Meeting*. Atlanta, GA. December 8-11, 2012.

122. Battaglia TA, McCoy ME, Caron SE, Mu HH, Bak SM, Baranoski AS, Freund KM, Chiao EY, Stier EA. Knowledge, Attitudes and Beliefs about Anal Cancer Screening among HIV-positive Women. Presentation. *28th International Papillomavirus Conference*. San Juan, Puerto Rico. December 2-6, 2012.

123. Battaglia TA, McCoy ME, Caron SE, Mu HH, Bak SM, Baranoski AS, Freund KM, Chiao EY, Stier EA. Knowledge, Attitudes and Beliefs about Anal Cancer Screening among HIV-positive Women. Poster presentation. *American Public Health Association (APHA) 140th Annual Meeting*. San Francisco, CA. October 27-31, 2012.

124. Barta SK, Xue X, Tamari R, et al. A pooled analysis of 1,144 patients with HIV-associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-specific Factors on Clinical Outcomes. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. June 1-5, 2012.

125. Garg M, Lee JY, Kachnic LA, Catalano PJ, Henry DH, Cooley TP, Ratner L, Wachsman W, Aboulafia DM, Benson AB, Palefsky J, Whittington R, Mitsuyasu RT, Sparano JA. Phase II Trials of Cetuximab (CX) plus Cisplatin (CDDP), 5-fluorouracil (5-FU) and Radiation (RT) in Immunocompetent (ECOG 3205) and HIV-positive (AMC-045) Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC): Safety and Preliminary Efficacy Results. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. June 1-5, 2012. **[AMC-]**



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

### **045]**

126. Gupta S, Jain P, Araujo E, French AL, Rosen FR, Rubinstein PG. A Retrospective Analysis of all Non-AIDS Defining Cancers (NADC): A Subset Analysis of the County Hospital AIDS Malignancy Project (CHAMP). Poster Presentation, Abstract #1611. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. June 1-5, 2012.
127. Rubinstein PG, Gupta S, Sreenivasappa SB, Jain S, Telfer MC, French AL, Mullane M. Concurrent Chemoradiotherapy with 5-fluorouracil and mitomycin C for Invasive Anal Carcinoma in HIV-positive Patients receiving Highly Active Antiretroviral Therapy vs. Non-HIV Patients. Poster Presentation, Abstract #e14590. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. June 1-5, 2012.
128. Sandhu S, Cisak K, Sreenivasappa SB, Batra KK, Gupta S, Mullane MR, Rubinstein PG. Adverse Events in Non-AIDS Defining Cancer Patients receiving Chemotherapy and Combined Antiretroviral Therapy. Poster Presentation, Abstract #e12523. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. June 1-5, 2012.
129. Sandhu S, Gupta S, Messinger M, Itokazu G, Braik T, Jain S, French AL, Rubinstein PG. Suspension of Ritonavir and Zidovadine Prevents Adverse Events during the Treatment of HIV Associated Hodgkin Lymphoma. Poster presentation, Abstract #8085. *American Society of Clinical Oncology (ASCO) Annual Meeting*, Chicago, IL. June 1-5, 2012.

### **2011**

130. Botello-Harbaum MT, Mosby K, Vena D, Aboulafia DM. The AIDS Malignancy Consortium (AMC): The Patient Navigator (PN) Research Program. *13<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. November 7-8, 2011.
131. Deeken JF, Rudek MA, Moore PC, Aboulafia D, Sullivan R, Gerecitano J, Cianfrocca M, Henry D, Ratner L, Dezube B, Mosby K, Tibbals M, Little RF, Ivy SP, Mitsuyasu RT. A Phase 1/PK Study of Sunitinib with Highly Active Antiretroviral Therapy (HAART) in HIV+ Patients with Solid Tumors: AIDS Malignancy Study 061. *13<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. November 7-8, 2011.
132. Epeldegui M, Widney DP, Martínez AC, Regidor D, Magpantay L, Mitsuyasu R, Sparano JA, Lee JY, Ambinder RF, Martínez-Maza O. Serum Levels of Several Molecules that are Associated with B Cell Activation and Inflammation are Elevated in AIDS-associated Non-Hodgkin's Lymphoma (AIDS-NHL) and Predict Response to Treatment. *13<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. November 7-8, 2011.
133. Hassane D, Padilla, Kim R, Giulino G, Matthew S, Tam W, Chadburn A, Barouk S, Adebamowo A, Leoncini L, Shet T, Rubin RA, Ceserman E. Gene Expression Profiling using Formalin-fixed Paraffin-embedded Primary Specimens of AIDS-related Lymphomas. Oral presentation. *13<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired*



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

*Immunodeficiencies (ICMAOI) Meeting.* Bethesda, MD. November 7-8, 2011.

- 134. Lee JY and Moore PC. Prevalence of HIV in Medical Beneficiaries with Lung Cancer. *13<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting.* Bethesda, MD. November 7-8, 2011.
- 135. Noy A, Kaplan L, Lee J, Cesarman E and Tam W. Modified Dose Intensive R- CODOX-M/IVAC for HIV-Associated Burkitt (BL) (AMC 048) Shows Efficacy and Tolerability, and Predictive Potential of IRF4/MUM1 Expression. *13<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting.* Bethesda, MD. November 7-8, 2011. **[AMC-048]**
- 136. Botello-Harbaum MT, Mosby K, Vena D, Aboulafia DM, and the PN Participating Investigators. The AIDS Malignancy Consortium (AMC): The Patient Navigator (PN) Initiative. *Society for Public Health Education's (SOPHE) 62<sup>nd</sup> Annual Meeting: Leveraging the Power of Health Education: Changing Systems.* Arlington, VA. October 27-29, 2011.
- 137. Botello-Harbaum MT, Stier EA, Mu H, Terada K, Shiramizu B, Aboulafia DM. Implementing AIDS Malignancy Consortium (AMC) Patient Navigators (PNs) in Anal Cancer Screening Programs. Poster presentation. *NCI Cancer Health Disparities Program Meetings.* Rockville, MD. July 12-15, 2011.
- 138. Shiramizu B, Milne C, Terada K, Cassel K, Zhu X, Kitamura K, Matsuno RK, Liang C-Y, Killeen J, Berry JM, Goodman M. Anal Cancer Screening using Self-Obtained Anal Pap Specimens from HIV-Infected Individuals. *NCI Cancer Health Disparities Program Meetings.* Bethesda, MD. July 12-15, 2011.
- 139. Noy A, Kaplan L, Lee J. Efficacy and tolerability of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and Atypical Burkitt Lymphoma (BL): Prospective Multicenter Phase II Trial of the AIDS Malignancy Consortium (AMC). *11<sup>th</sup> International Conference on Malignant Lymphoma (ICML).* Lugano, Switzerland. June 15-18, 2011.
- 140. Mitsuyasu RM. Conducting Clinical Trials in Resource Low-Income Countries: Challenges and Opportunities. Poster presentation. *American Society of Clinical Oncology (ASCO) Annual Meeting.* Chicago, IL. June 6, 2011.
- 141. Koon HB, Honda K, Lee JY, Egorin MJ, Noy A, for the AIDS Malignancy Consortium. AMC-042: Phase II AIDS Malignancy Consortium (AMC) Trial of Imatinib in AIDS-associated Kaposi's Sarcoma (KS). Poster presentation. *American Society of Clinical Oncology (ASCO) Annual Meeting.* Chicago, IL. June 3-7, 2011. **[AMC-042]**
- 142. Deeken JF, Moore PC, Aboulafia D, Sullivan R, Gerecitano J, Cianfrocca M, Henry D, Ratner L, Dezube B, Mosby K, Tibbals M, Little RF, Ivy SP, Rudek MA, Mitsuyasu RT. AIDS Malignancy Consortium (AMC) Study 061: A Phase 1/PK Study of Sunitinib (S) with Highly Active Antiretroviral Therapy (HAART) in HIV+ Patients with Solid Tumors. Poster presentation. *American Society of Clinical Oncology (ASCO) Annual Meeting.* Chicago, IL. June 3-7, 2011. **[AMC-061]**



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

143. Shimabukuro K, Reid E, for the AMC 070 Study Team. AMC 070: A Phase I/II Study of Lenalidomide in Patients with AIDS-Associated Kaposi Sarcoma. Poster presentation. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. June 3-7, 2011. **[AMC-070]**
144. Botello-Harbaum MT, Aboulafia D, Mosby K, Vena D, Chiao E, Sadler G, and the PNs Participating Investigators. The AIDS Malignancy Clinical Trials Consortium (AMC): Patient Navigator PN Initiative. Poster presentation. *American Association for Cancer Research 102<sup>nd</sup> Annual Meeting Innovation and Collaboration: The Path to Progress*. Orlando, FL. April 2-6, 2011.

### **2010**

145. Barta SK, Lee JY, Sparano JA, Kaplan LD, Noy A, on behalf of the AIDS Malignancy Consortium. Pooled Analysis of AIDS Malignancy Consortium Trials Evaluating Rituximab Plus Either CHOP or Infusional EPOCH Chemotherapy in HIV-Associated Non-Hodgkin's Lymphoma. *American Society of Hematology (ASH) Annual Meeting*. December 2010.
146. Noy A, Bayraktar UD, Gupta N, Petrich A, Moore P, Lensing S, for the AIDS Malignancy Consortium. Outcome of Patients with Relapsed/Refractory AIDS-Related Lymphoma. *American Society of Hematology (ASH) Annual Meeting*. December 2010.
147. Dittmer DP, Roy D, Krown S, Damania B. Why is Rapamycin Effective against Kaposi Sarcoma? An Analysis of Molecular Pathways Reveals Epigenetic Silencing of PTEN. *22<sup>nd</sup> EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics*. Berlin, Germany. November 16-19, 2010.
148. Palefsky J, Wilkin T, Giuliano A, for the Male Quadrivalent HPV Vaccine Efficacy Trial Team and AIDS Malignancy Consortium 052 study teams. Lower Level of Titers in Response to the HPV Quadrivalent Vaccine among Men who have Sex with Men compared with Heterosexual Men. *HPV 2010 Meeting*. Montreal Canada. July 3-8, 2010.
149. Stier EA, Goldstone SE, Einstein MH, Jay N, Berry JM, Wilkin T, Lee J, Panther LA, Aboulafia D, Palefsky JM. Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Neoplasia in HIV-Infected Men and Women (AMC-046). *International Papillomavirus Conference*. Montréal, Canada. July 3-8, 2010. **[AMC-046]**
150. Deeken JF, Mitsuyasu RT, Little RF, Ivy SP, Ambinder RF, Rudek MA, Lee JY, Moore PC, Mosby K, Dezube BJ. Treating HIV+ Patients for Non-AIDS Defining Cancers (NADCs) in the Era of Targeted Chemotherapy: An AIDS Malignancy Consortium Study of Sunitinib in Patients on ART. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. June 4-8, 2010.
151. Sunil M, Mixon T, Reid E, Lechowicz MJ. HIV- Related Hodgkin Lymphoma in the HAART Era: A Comprehensive Review and Meta-Analysis of Response and Survival Rates. Poster presentation. *American Society of Hematology (ASH) Annual Meeting*. Rio de Janeiro, Brazil. May 14-15, 2010.



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

152. Botello-Harbaum MT, Aboulafia D, Vena D, Mosby K, and the Patient Navigator Participating Investigators. The AIDS Malignancy Clinical Trials Consortium (AMC) Patient Navigator (PN) Initiative. Poster presentation. *NCI-American Society for Clinical Oncology. Cancer Trial Accrual Symposium*. Bethesda, MD. April 29-30, 2010.
153. Koon HB, Honda K, Lee JY, Egorin MJ, Noy A for the AIDS Malignancy Consortium. Phase II AIDS Malignancy Consortium (AMC) Trial of Imatinib in AIDS-associated Kaposi's Sarcoma (KS). *12<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 26-27, 2010. **[AMC-042]**
154. Palefsky J, Wilkin T, Giuliano A, for the Male Quadrivalent HPV Vaccine Efficacy Trial Team and AIDS Malignancy Consortium 052 study teams. Lower Level of Titers in Response to the HPV Quadrivalent Vaccine among Men who have Sex with Men compared with Heterosexual Men. *12<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 26-27, 2010.
155. Krown SE, Fingleton B, Lee JY, Egorin MJ, Koon HB for the AIDS Malignancy Consortium. Phase II AIDS Malignancy Consortium (AMC) Trial of Topical Halofuginone in AIDS-associated Kaposi's Sarcoma (KS): Clinical and Biological Effects using a Novel Intra-Patient Control Design. *12<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 26-27, 2010. **[AMC-036]**
156. Sunil M, Reid E, Lechowicz MJ. Autologous Stem Cell Transplantation (ASCT) for HIV-Related Lymphomas in the HAART Era: A Meta-Analysis of Response and Survival Post Transplant. Poster presentation. *BMT Tandem Meeting*. Orlando, FL. February 24-28, 2010.
157. Wilkin TJ, Lee JY, Goldstone SE, Stier EA, Berry JM, Aboulafia D, Cohn DL, Einstein MH, Mitsuyasu RT, Palefsky JM. Safety and Immunogenicity of the Quadrivalent HPV vaccine (qHPV) in HIV-Infected Men: Primary Results of AIDS Malignancy Consortium Trial 052. *17<sup>th</sup> Conference on Retroviruses and Opportunistic Infections*. San Francisco, CA. February 16-19, 2010.
158. Zota V, Braza J, Pantanowitz L, Dezube BJ, Pihan G. Safety and Immunogenicity of the Quadrivalent HPV vaccine (qHPV) in HIV-Infected Men: Primary Results of AIDS Malignancy Consortium Trial 052. *17<sup>th</sup> Conference on Retroviruses and Opportunistic Infections*. San Francisco, CA. February 16-19, 2010.

### **2009**

159. Sunil M, Mixon T, Reid E, Lechowicz MJ. HIV Related Hodgkin's Lymphoma in the HAART Era: A Comprehensive Review and Meta-Analysis of Response and Survival Rates. *Blood*. November 2009. Volume 114; Issue 22; Abstract 1652.
160. Ayers LW, Tumwine LK. Sub-Saharan Africa Lymphoma Consortium (SSALC): Understanding Lymphoma Phenotypes in Africa; Building Capacity for Future Treatments (Abstract nos. 327). Cancer and HIV, Workshop 2.2.4, convened by NCI. *African Organization for Research & Training in Cancer (AORTIC), 7<sup>th</sup> International Conference*. Dar es Salaam, Tanzania. November 13, 2009.



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

161. Orem J, Yu JJ, Fu P, Pink JJ, Dawson D, Wasman J, Mwanda WO, Zhu X, Mitsuyasu R, Wabinga H, Remick SC. HPV Infection and EGFR Activation/Alteration in the Development of Conjunctival Cancer among HIV-infected Patients in East Africa (Abstract nos. 277). *African Organization for Research & Training in Cancer (AORTIC), 7<sup>th</sup> International Conference*. Dar es Salaam, Tanzania. November 13, 2009.
162. Remick, SC. Building Partnerships in Africa to Develop Effective Treatment and Prevention Strategies for AIDS-related Cancers. Cancer and HIV, Workshop 2.2.4, convened by NCI. *African Organization for Research & Training in Cancer (AORTIC), 7<sup>th</sup> International Conference*. Dar es Salaam, Tanzania. November 13, 2009.
163. Qaiyumi S, Marshall JL, Hwang J, Dawson N, Cheson BD, Timpone Jr. J, Kumar PN, Deeken JF. Treating HIV Patients on HAART Therapy for Non-AIDS Defining Cancers: A Single Institutional Experience. *American Medical Association RFS 2009 Research Symposium*. November 7, 2009, Orlando FL.
164. Krown SE, Dittmer PD. AIDS Malignancy Consortium (AMC) Study of Rapamycin in Patients with HIV-Associated Kaposi's Sarcoma (KS). *International Workshop on Kaposi's Sarcoma Herpes Virus (KSHV) and Related Agents Workshop*. Charleston, SC. September 13-16, 2009. **[AMC-051]**

### 2008

165. Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, Ramos JC, Luz E, Pedroso C, Manrique M, Toomey NL, Brites C, Dittmer D, Harrington WJ. Epstein-Barr Virus MicroRNAs in Primary Lymphomas and Targeting of CXCL-11 by ebv-mir-BHRF1-3. *The Viral Oncology Program*, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL. *The Department of Microbiology and Immunology*, Curriculum in Genetics and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. *The Federal University of Bahia*, Salvador, Bahia, Brazil. Hospital Areteides Maltez, Salvador Bahia, Brazil. Hospital Martagao Gesteira, Salvador Bahia, Brazil. 2008.
166. Sparano J, Levine A. Efficacy and Toxicity of Concurrent Rituximab Plus Infusional EPOCH in HIV-associated Lymphoma: AIDS Malignancy Consortium Trial 034. *American Society of Clinical Oncology (ASCO) Meeting*. Chicago, IL. May 30-June 3, 2008.
167. Xia T, Chaput A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, Ramos JC, Luz E, Pedroso C, Manrique M, Toomey NL, Brites C, Dittmer D, Harrington WJ. EBV MicroRNAs in Primary Lymphomas and Targeting of CXCL-11 by ebv-mir-BHRF1-3. *American Association for Cancer Research*. March 1, 2008; 68:(5)1-7.

### 2007

168. Lechowicz MJ, Lee J, Dittmer D, Krown S, Said J, Ambinder R, for the AIDS Malignancy Consortium and the AIDS and Cancer Specimen Resource. A Pilot Trial of Valproic Acid in Patients with Kaposi's Sarcoma: A Multi-Center Trial of the AIDS Malignancy Consortium. *American Society of Hematology (ASH) Meeting*. Atlanta, GA. December 2007.



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

169. Von Roenn JH, Lee S, Cianfrocca M, Tulpule A, Scadden D, Aboulafia D, Sparano J. Phase III Study of Paclitaxel (Pac) versus Pegylated Liposomal Doxorubicin for the Treatment of Advanced Human Immunodeficiency Virus (HIV)-associated Kaposi's Sarcoms (KS): An Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium. 2007 *American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings Part I of II, Supplement to Journal of Clinical Oncology, 43rd Annual Meeting*. Chicago, IL. June 1-5, 2007; Supplement 20503: Volume 25, No. 18S.

### 2006

170. Chadburn A, Chen X, Chiu A, Hyjek E, Tam W, Kaplan LD, Scadden DT, Knowles DM, Cesarman E. Neither Germinal Center (GC) vs. Non-germinal Center (Non-GC) Phenotype nor FOXP1 Correlate with Outcome in AIDS-associated Diffuse Large B Cell Lymphoma (DLBCL): Study of Patients from AIDS Malignancies Consortium Trials 010 and 034. *American Society of Hematology (ASH) Meeting*. Orlando, FL. December 2006.

171. Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Ness A, Johnson J, Subbiah V, Bako J, Black J, Kalongeole-Mbidde E, Remick SC. Dose-modified Oral Chemotherapy for AIDS-related Non-Hodgkin's Lymphoma in East Africa: Impact on CD4+ Count and HIV Replication. *48th American Society of Hematology (ASH) Annual Meeting*. Orlando, FL. December 2006.

172. Mwanda WO, Whalen C, Remick SC, Lederman M, Orem J, Banura C. The Homing Concept of Virally-associated Malignancies. *10th Brazilian Congress on Oncology Pediatrics*. Salvador, Brazil. November 2006.

173. Chiu A, Chen X, Cesarman E, Hyjek E, Kaplan LD, Scadden DT and Chadburn A. FOXP1 Expression in AIDS-associated Diffuse Large B-cell Lymphoma (DLBCL): Correlation with Prognostic Parameters in Patients from AIDS Malignancies Consortium Trials 010 and 034. *10th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting: Basic, Epidemiologic and Clinical Research*. Bethesda, MD. October 15-17, 2006.

174. Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Ness A, Johnson J, Subbiah V, Bako J, Black J, Kalongeole-Mbidde E, Remick SC. Dose-modified Oral Chemotherapy for AIDS-related Non-Hodgkin's Lymphoma in East Africa: Impact on CD4+ Count and HIV Replication. *10th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting: Basic, Epidemiologic and Clinical Research*. Bethesda, MD. October 15-17, 2006.

175. Sparano JA, Lee JY, Kaplan LD. Randomized Phase II Trial of Infusional EPOCH Chemotherapy given Concurrently or Sequentially with Rituximab in HIV-associated Lymphoma (AMC-034). *10th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting: Basic, Epidemiologic and Clinical Research*. Bethesda, MD. October 15-17, 2006. **[AMC-034]**

176. Stier EA. Infrared Coagulator (IRC) for Treatment of High Grade Squamous Intraepithelial Neoplasia (HSIL) of the Anal Canal in HIV-infected Individuals: A Pilot Study (AMC-032).



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

*10<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Meeting: Basic, Epidemiologic and Clinical Research.*  
Bethesda, MD. October 15-17, 2006. [\[AMC-032\]](#)

177. Orem J, Mwanda WO, Banura C, Katongole-Mbidde E, Johnson JL, Ayers L, Ghannoum M, Fu P, Whalen C, Lederman M, Remick SC. Capacity Building for the Clinical Investigation of AIDS Malignancy in East Africa. *Union for International Cancer Control (UICC) World Cancer Congress 2006*. Washington, D.C. July 7-12, 2006.
178. Chen X, Ceserman E, Hyjek E, Kaplan LD, Scadden DT, Chadburn A. FOXP1 Expression in AIDS-associated Diffuse Large B-Cell Lymphoma (DLBCL): Correlation with Prognostic Parameters in Patients from AIDS Malignancies Consortium Trial 010. *United States and Canadian Academy of Pathology (USCAP) Meeting*. Atlanta, GA. February 13-16, 2006.

### 2005

179. Aboulafia DM, Ratner L, Miles SA, Lee JY, Harrington WJ. AMC-019: A Pilot Study of Antiviral and Immunomodular Treatment for HIV-associated Primary CNS Lymphoma (PCNSL). *9<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. September 25-27, 2005. [\[AMC-019\]](#)
180. Palefsky J, Berry M, Jay N, Krogstad M, Darragh T, Lee J. AMC-035: A Phase I/II Trial of SGN-00101 in the Treatment of High-grade Anal Intraepithelial Neoplasia (AIN) in HIV-positive Individuals. *9<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. September 25-27, 2005. [\[AMC-035\]](#)
181. Banura C, Orem J, Bitamazire E, Weiderpass E, Whalen CC, Remick SC, Katongole-Mbidde E. Clinical Presentation of Epidemic and Endemic Kaposi's Sarcoma in Ugandan Children. *27<sup>th</sup> Annual Meeting of the International Association of Cancer Registries (IACR)*. Entebbe, Uganda. September 13-15, 2005.

### 2004

182. Dezube BJ for the AIDS Malignancy Consortium. Angiogenesis Inhibitor COL-3 in the Treatment of HIV-related Kaposi's Sarcoma (KS): A Phase II AIDS Malignancy Consortium Study. *8<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 29-30, 2004. [\[AMC-027\]](#)
183. Lee J for the AIDS Malignancy Consortium. Pain and Appearance are Related to Response to Treatment in AIDS-related Kaposi's Sarcoma. *8<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 29-30, 2004. [\[AMC-002 and AMC-013\]](#)
184. Lin L for the AIDS Malignancy Consortium. KSHV (HHV8) DNA in Peripheral Blood of Patients with AIDS-NHL and the Impact of Chemotherapy. *8<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 29-30, 2004. (LAB-based)



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

### 2003

185. Kaplan LD, Scadden DT, for the AIDS Malignancies Consortium. No Benefit from Rituximab in a Randomized Ph III Trial of CHOP with or without Rituximab for Patients with HIV-associated Non-Hodgkin's Lymphoma: AIDS Malignancies Consortium Study 010. *American Society of Hematology (ASCO) Meeting*. San Diego, CA. December 2003. **[AMC-010]**
186. Lin L, Ambinder RF, Fisher DC, Mauch P, for the AIDS Malignancy Consortium. Epstein-Barr Virus Load in Plasma of Patients with AIDS Malignancy Reflects EB Viremia and Free EB Viral DNA (DNA-emia) whereas in EBV (+) Hodgkins Lymphoma It Reflects only DNA-emia. *Blood*. November 16, 2003; 102 (11), Abstract #4850. (LAB-based)
187. Kaplan LD, Lee J, Caligiuri M, Von Roenn J, Levine A, Harrington W, Scadden D, for the AIDS-associated Malignancies Consortium. A Randomized Phase III Trial of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) with or without Rituximab for Patients with HIV-associated Non-Hodgkin's Lymphoma: AIDS Malignancies Consortium Study 010. *American Society of Clinical Oncology (ASCO) Meeting*. Chicago, IL. June 2003. **[AMC-010]**
188. Dezube BJ, Tseng G, Fugelso D, Greenberg H, Nasser I, Wei LJ, Chatis PA. Microarray Expression Profile in High-Grade and Low-Grade Squamous Intraepithelial Lesions. *7<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 28-29, 2003.
189. Kaplan LD, Scadden DT, for the AIDS Malignancies Consortium. No Benefit from Rituximab in a Randomized Ph III Trial of CHOP with or without Rituximab for Patients with HIV-associated Non-Hodgkin's Lymphoma: AIDS Malignancies Consortium Study 010. *7<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 28-29, 2003. **[AMC-010]**
190. Koon H, Bubley G, Pantanowitz L, Masiello D, Proper J, Weeden W, Smith B, Crosby K, Tahan SR, Dezube BJ. AIDS-related Kaposi's Sarcoma: Imatinib Mesylate-induced Regression in c-KIT Positive Disease. *7<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 28-29, 2003.
191. Mwanda WO, Orem J, Banura C, Katongole-Mbidde E, Johnson J, Ness A, Reynolds S, Black J, Feigal E, Fu P, Whalen C, Remick SC. Preliminary Observations Using Dose-Modified Oral Combination Chemotherapy (DMOCC) for AIDS-related Non-Hodgkin's Lymphoma (AR-NHL) in East Africa: Toxicity & Vital Status. *7<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 28-29, 2003.
192. Orem J, Mwanda WO, Banura C, Katongole-Mbidde E, Fu P, Johnson J, Ness A, Reynolds S, Black J, Feigal E, Whalen C, Remick SC. Prospective Screening for AIDS-Related Non-Hodgkin's Lymphoma (AR-NHL) Patients (PTS) in East Africa as Part of a Clinical Trial. *7<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 28-29, 2003.
193. Pantanowitz L, Tahan SR, Pinkus GS, Dezube BJ. Morphology and Mechanisms of Regression in



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

AIDS-Related Kaposi's Sarcoma (KS). *7<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies*. Bethesda, MD. April 28-29, 2003.

194. Von Roenn JH for the AIDS Malignancy Consortium. Phase I-II trial of BMS-275291 in Patients with HIV-related Kaposi's Sarcoma: A multicenter trial of the AIDS Malignancy Consortium. *7<sup>th</sup> International Conference on Malignancies in AIDS and Other Immunodeficiencies (ICMAOI) Meeting*. Bethesda, MD. April 28-29, 2003. **[AMC-024]**
195. Woodberry T, Henry L, O'Connor P, Davis J, Lee J, Kaplan L, Khayrallah M, Osmond D, Martin J, Scadden D, Brander C, and the AIDS Malignancy Consortium. Mediated Immune Response to KSHV ORF65 and ORF73 in Individuals with and without KS. *7<sup>th</sup> International AIDS Malignancy Conference*. Bethesda, MD. April 28-29, 2003. (LAB-based)

### 2002

196. Lin L, Kaplan L, Lee J, Chadburn A, Cesarman E, Herman JG, Ambinder RF, and the AIDS Malignancy Consortium. Monitoring Epstein-Barr Virus Load in Peripheral Blood in AIDS-related Lymphoma Patients: An AIDS Malignancy Consortium Laboratory Study. *American Society of Hematology (ASH) Meeting*. Philadelphia, PA. December 2002. (LAB-based)
197. Noy A, Gill P, Scadden D, Lee J, Dezube B, Aboulafia D, Tulpule A, Walmsley S, for the AIDS Malignancy Consortium and IM862 Team. Angiogenesis Inhibitor IM862 is Ineffective against AIDS-KS in a Randomized, Placebo Controlled Trial. *6<sup>th</sup> International AIDS Malignancy Conference*. Bethesda, MD. April 22-24, 2002. **[AMC-013]**

### 2001

198. Cianfrocca M, Cooley TP, Tan S, et al. Angiogenesis Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma (KS): Final Clinical Analysis and Report of Effects on Matrix Metalloproteinase (MMP) and Growth Factor Levels. *5<sup>th</sup> International AIDS Malignancy Conference*. Bethesda, MD. April 23-25, 2001.

### 2000

199. Cianfrocca M, Cooley TP, Lee J, Scadden DT, Ratner L, Dezube BJ. Angiogenesis Inhibitor Col-3 in the Treatment of HIV-related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study. *4<sup>th</sup> International AIDS Malignancy Conference*. Bethesda, MD. May 16-18, 2000. **[AMC-011]**

### 1999

200. Ratner L, Redden D, Hamzeh F, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D, for the AIDS Malignancy Consortium (AMC). Chemotherapy for HIV-associated Non-Hodgkin's Lymphoma (HIV-NHL) in Combination with Highly Active Antiretroviral Therapy (HAART) is not Associated with Excessive Toxicity. *3<sup>rd</sup> International AIDS Malignancy Conference*. Bethesda, MD. May 26-27, 1999.

### 1998

201. Straus D, Redden D, Hamzeh F, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W,



## ABSTRACTS/PRESENTATIONS – *cont'd*

*Last Updated: February 5, 2026*

Grochow L, Flexner C, Tan B, Ratner L, for the AIDS Malignancy Consortium (AMC). Excessive Toxicity is not seen with Low-Dose Chemotherapy for HIV-associated Non-Hodgkin's Lymphoma (HIV-NHL) in Combination with Highly Active Antiretroviral Therapy (HAART). *American Society of Hematology (ASH) Meeting*. Miami, FL. December 4-8, 1998.

202. Lee J, Miles S, Friedman-Kien A, for the NCI AIDS Malignancies Consortium. Suspending Enrollment in a Two-Stage Phase II AIDS Malignancies Consortium Trial of AIDS Kaposi's Sarcoma Patients. *Society for Clinical Trials*. Atlanta, GA. May 1998. **[AMC-002]**

203. Miles SA, Dezube B, Lee J, Groopman J, Saville W, Scadden D, Debruge J, Friedman-Kien, AMC-002 Team. Oral LGD1057 is Active in AIDS Related Kaposi's Sarcoma: An AIDS Malignancies Consortium Trial (AMC-002). *American Society of Clinical Oncology (ASCO)*. Los Angeles, CA. May 1998. **[AMC-002]**

204. Friedman-Kien A, Dezube B, Lee J, Groopman J, Saville W, Scadden DT, Debruge J, Miles S, AMC-002 Team. Oral 9-cis Retinoic Acid is Active in AIDS-Related Kaposi's Sarcoma: AIDS-associated Malignancy Consortium Study 002. *2<sup>nd</sup> International AIDS Malignancy Conference*. Bethesda, MD. April 6-8, 1998. **[AMC-002]**

205. Lee J, Miles SA, Dezube B, Kaplan L, Groopman J, Saville W, Scadden D, Debruge J, Friedman-Kien A, AMC-002 Team. Recruitment in a Two-Stage Phase II Trial of AIDS Kaposi's Sarcoma. *2<sup>nd</sup> International AIDS Malignancy Conference*. Bethesda, MD. April 6-8, 1998. **[AMC-002]**